Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales (“MERINO-3”): study protocol for a multicentre, open-label randomised non-inferiority trial

[1]  L. Leibovici,et al.  Piperacillin–tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen) , 2021, BMJ Open.

[2]  Versione,et al.  Common Terminology Criteria for Adverse Events , 2020, Definitions.

[3]  K. Kazmierczak,et al.  In vitro activity of ceftolozane/tazobactam against phenotypically defined extended-spectrum β-lactamase (ESBL)-positive isolates of Escherichia coli and Klebsiella pneumoniae isolated from hospitalized patients (SMART 2016). , 2019, Diagnostic microbiology and infectious disease.

[4]  S. Beatson,et al.  Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial , 2018, JAMA.

[5]  Publisher's Note , 2018, Anaesthesia.

[6]  M. Castanheira,et al.  Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013–2015) , 2017, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[7]  L. Leibovici,et al.  Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[8]  S. Cosgrove,et al.  Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR). , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  Michael Bailey,et al.  Systemic inflammatory response syndrome criteria in defining severe sepsis. , 2015, The New England journal of medicine.

[10]  P. Barie,et al.  Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI) , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  W. Ko,et al.  Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  V. Cheng,et al.  Clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteremia in an area with high endemicity. , 2013, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[13]  M. Falagas,et al.  Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. , 2012, The Journal of antimicrobial chemotherapy.

[14]  J. Alonso,et al.  Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric cohort study , 2012, BMC Infectious Diseases.

[15]  Chien-Te Lee,et al.  Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum beta-lactamase producing klebsiella pneumoniae in patients on maintenance hemodialysis , 2012, BMC Infectious Diseases.

[16]  K. Kaye,et al.  Impact of Cefepime Therapy on Mortality among Patients with Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae and Escherichia coli , 2012, Antimicrobial Agents and Chemotherapy.

[17]  J. Rodríguez-Baño,et al.  β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  M. Bassetti,et al.  Will new antimicrobials overcome resistance among Gram-negatives? , 2011, Expert review of anti-infective therapy.

[19]  Samuel M. Brown,et al.  A Modified Sequential Organ Failure Assessment Score for Critical Care Triage , 2010, Disaster Medicine and Public Health Preparedness.

[20]  H. Goossens,et al.  Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  D. Paterson.  "Collateral damage" from cephalosporin or quinolone antibiotic therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  D. F. Sahm,et al.  AmpC beta-lactamases. , 1998 .

[23]  J. Gold,et al.  Validation of a combined comorbidity index. , 1994, Journal of clinical epidemiology.

[24]  D. Paterson,et al.  Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials , 2017, The Journal of antimicrobial chemotherapy.